PMID- 33766229
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20211204
IS  - 1007-8738 (Print)
IS  - 1007-8738 (Linking)
VI  - 37
IP  - 3
DP  - 2021 Mar
TI  - [Astragaloside II inhibits the proliferation of rat pulmonary artery smooth 
      muscle cells induced by hypoxia via blocking NOX/ROS/AKT/mTOR signaling pathway].
PG  - 219-224
AB  - Objective To investigate the inhibitory effect of astragaloside II (AS-II) on the 
      proliferation of pulmonary artery smooth muscle cells (PASMCs) induced by hypoxia 
      and its relevant mechanism. Methods Rat primary PASMCs were divided into normoxia 
      group, hypoxia group, hypoxia combined with 20, 40, 80 mumol/L AS-II treated 
      groups, hypoxia combined with nicotinamide adenine dinucleotide phosphate (NADPH) 
      oxidase (NOX) inhibitor VAS2870 treated group, and then cultured either in 
      normoxic (210 mL/L O(2)) or hypoxic (20 mL/L O(2)) condition for 24 hours. The 
      proliferation of PASMCs was detected by CCK-8 assay. The level of intracellular 
      reactive oxygen species (ROS) was detected by DCFH-DA staining. Protein kinase B 
      (AKT), phospho-AKT (p-AKT), mammalian target of rapamycin (mTOR), phospho-mTOR 
      (p-mTOR), proliferating cell nuclear antigen (PCNA), NOX1 and NOX4 protein 
      expression were assessed by Western blotting. Results In the hypoxia group, the 
      proliferation of PASMCs, level of intracellular ROS, protein expression of PCNA, 
      p-AKT, p-mTOR, NOX1 and NOX4 increased significantly compared with those in the 
      normoxia group. However, AS-II treatment inhibited hypoxia-induced PASMCs 
      proliferation, decreased the level of intracellular ROS, and suppressed protein 
      expression of PCNA, p-AKT, p-mTOR, NOX1 and NOX4. Moreover, VAS2870 treatment 
      lead to similar changes. Conclusion AS-II can inhibit the proliferation of PASMCs 
      induced by hypoxia, which may be associated with the blocking of NOX/ROS/AKT/mTOR 
      signaling pathway.
FAU - Jin, Haifeng
AU  - Jin H
AD  - Department of Anatomy, Qigihar Institute of Medical and Pharmaceutical Sciences, 
      Qiqihar Medical University, Qiqihar 161006, China.
FAU - Yao, Lijie
AU  - Yao L
AD  - Department of Anatomy, Qiqihar Medical University, Qiqihar 161006, China.
FAU - DU, Fengxia
AU  - DU F
AD  - Department of Etiology, Qiqihar Medical University, Qiqihar 161006, China.
FAU - Jiang, Yang
AU  - Jiang Y
AD  - Department of Anatomy, Qiqihar Medical University, Qiqihar 161006, China.
FAU - Li, Xuemei
AU  - Li X
AD  - Experiment and Practice Training Center, Qiqihar Medical University, Qiqihar 
      161006, China.
FAU - Zhang, Yuting
AU  - Zhang Y
AD  - Department of Anatomy, Qiqihar Medical University, Qiqihar 161006, China.
FAU - Wang, Guan
AU  - Wang G
AD  - Department of Anatomy, Qiqihar Medical University, Qiqihar 161006, China.
FAU - Liu, Jicheng
AU  - Liu J
AD  - Qigihar Institute of Medical and Pharmaceutical Sciences, Qiqihar Medical 
      University, Qiqihar 161006, China. *Corresponding authors, E-mail: 
      jcliu@qmu.edu.cn.
FAU - Zhou, Zhongguang
AU  - Zhou Z
AD  - Basic Discipline of Integrated Chinese and Western Medicine, Heilongjiang 
      University of Chinese Medicine, Harbin 150000, China. *Corresponding authors, 
      E-mail: zzg5709@163.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
JT  - Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular 
      immunology
JID - 101139110
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Saponins)
RN  - 0 (astragaloside II)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Cell Hypoxia
MH  - Cell Proliferation
MH  - Cells, Cultured
MH  - Hypoxia
MH  - Myocytes, Smooth Muscle/metabolism
MH  - *Proto-Oncogene Proteins c-akt/metabolism
MH  - *Pulmonary Artery/metabolism
MH  - Rats
MH  - Reactive Oxygen Species
MH  - Saponins
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases
EDAT- 2021/03/27 06:00
MHDA- 2021/03/30 06:00
CRDT- 2021/03/26 05:52
PHST- 2021/03/26 05:52 [entrez]
PHST- 2021/03/27 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PST - ppublish
SO  - Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2021 Mar;37(3):219-224.